MorphoSys' Q4 Sales Rise 44 Percent as Profit Turns to Loss on R&D, Restructuring Costs | GenomeWeb
NEW YORK (GenomeWeb News) — MorphoSys today said fourth-quarter revenues increased 44 percent as operating expenses, coming largely from R&D, spiked 115 percent and profit turned to a loss.
 
Total receipts for the three months ended Dec. 31, 2006, increased to €14 million ($18.5 million) from €9.7 million year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.